SCHEMBL6676374

SCHEMBL6676374

COC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 5/20 0.78
EPHA2 P29317 3/20 0.78
LMNA P02545 3/20 0.78
HSD17B10 Q99714 3/20 0.78
TDP1 Q9NUW8 3/20 0.78
MEN1 O00255 2/20 0.78
KMT2A Q03164 2/20 0.78
AKR1B10 O60218 2/20 0.78
AKR1B1 P15121 2/20 0.78
EFNA1 P20827 1/20 0.78
PSEN1 P49768 1/20 0.78
PSEN2 P49810 1/20 0.78
APH1B Q8WW43 1/20 0.78
NCSTN Q92542 1/20 0.78
APH1A Q96BI3 1/20 0.78
PSENEN Q9NZ42 1/20 0.78
HIF1A Q16665 3/20 0.76
VDR P11473 2/20 0.76
CYP2C9 P11712 2/20 0.76
MAPT P10636 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18576000 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL19313991 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL18844053 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL14544659 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL21752770 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL24151937 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL16892648 1.00 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL28266346 0.94 GPBAR1 (0.72) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL8965370 0.92 GPBAR1 (0.78) GPBAR1EPHA2LMNAHSD17B10TDP1
SCHEMBL27513055 0.91 GPBAR1 (0.77) GPBAR1EPHA2LMNAHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930728-A Efficient synthesis method of 3-oxo-4, 22-diene cholanic acid-24 methyl ester 浙江工业大学 2025-05-06 CN claimed
CN-104398504-A Deoxypodophyllotoxin medicine-containing pharmaceutical composition and preparation method and preparation thereof Zhejiang jianfeng pharmaceutical co ltd 2015-03-11 CN claimed
CN-119930728-A Efficient synthesis method of 3-oxo-4, 22-diene cholanic acid-24 methyl ester 浙江工业大学 2025-05-06 CN disclosed
CN-119930728-A Efficient synthesis method of 3-oxo-4, 22-diene cholanic acid-24 methyl ester 浙江工业大学 2025-05-06 CN disclosed
CN-119930728-A Efficient synthesis method of 3-oxo-4, 22-diene cholanic acid-24 methyl ester 浙江工业大学 2025-05-06 CN disclosed
CN-119684165-A Cholesteric molecular clamp artificial receptor and method for detecting zinc ions in food by using same 青海大学 2025-03-25 CN disclosed
CN-118994287-A Preparation method of alpha-rat bile acid intermediate 浙江工业大学 2024-11-22 CN disclosed
CN-113264972-B Method for preparing obeticholic acid 四川科伦药物研究院有限公司 2024-07-12 CN disclosed
CN-113330020-B 2-fluoro bile acids for the treatment of neurodegenerative diseases NZP英国有限公司 2024-04-05 CN disclosed
WO-2023227723-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ARAMCHOL AND SALTS THEREOF PHARMAZELL GMBH (DE) 2023-11-30 WO disclosed
US-11617804-B2 Hyaluronic acid-based nanoparticles as biosensors for imaging-guided surgery and drug delivery vehicles and methods associated therewith WAKE FOREST UNIVERSITY (US) 2023-04-04 US disclosed
CN-106008639-A Cholanic acid compounds for preventing or treating FXR-mediated diseases 深圳市塔吉瑞生物医药有限公司 2016-10-12 CN disclosed
CN-104853758-A Treatment of pulmonary disease INTERCEPT PHARMACEUTICALS INC 2015-08-19 CN disclosed
CN-104398504-A Deoxypodophyllotoxin medicine-containing pharmaceutical composition and preparation method and preparation thereof Zhejiang jianfeng pharmaceutical co ltd 2015-03-11 CN disclosed
EP-1966228-B1 PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID DAEWOONG BIO INC (KR) 2015-01-21 EP disclosed
EP-1960416-B1 PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID DAE WOONG PHARMA (KR) 2014-12-31 EP disclosed
CN-103143027-A Preparation of hyaluronic-acid-based double-targeting nano-composite medicament and application of double-targeting nano-composite medicament UNIV XIAMEN 2013-06-12 CN disclosed
US-20120309700-A1 DEVELOPMENT AND EVALUATION OF NOVEL CHINESE MATERIA MEDICA PREPARATIONS SONG CHING (CN) 2012-12-06 US disclosed
CN-101497641-A Method for synthesizing delta 24(28) cholesterol compounds THIRD MILTARY MEDICAL UNIVERSI (CN) 2009-08-05 CN disclosed
WO-2004037275-A1 BILE ACID CONJUGATES AND PARTICLES FORMED THEREWITH WIELAND, HEINRICH (DE) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11617804-B2 Hyaluronic acid-based nanoparticles as biosensors for imaging-guided surgery and drug delivery vehicles and methods associated therewith CD44, HLA-A, HLA-C GPBAR1 349/4885EPHA2 47/4885LMNA 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.